Screened 2026-09-08 · the tape above runs as of 19:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Cencora holds its Distribution at $324.69. Consolidating, no directional conviction, held for 2 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 2 days
Price at the screen
$324.69
Valuation
24.10 trailing · 16.42 forward price to earnings
Values screen
PASS· score 86.5
Beta
0.57
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
10.00%
Below 33%
Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
38.62%
Below 49%
Money owed to the company is 38.6% of assets, under the 49% limit.
Pass
Revenue purity
0.04%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OPPORTUNITY: it trades at roughly a 24% discount to our $402.57 fair value, weak competitive moat, 5.10% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 24.0% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Buy. The average target sits +14% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Pharma distributor offers margin of safety today
Every hospital ward and corner pharmacy needs a steady flow of medicines and supplies. Cencora moves those products across the United States and beyond. The shares sit at a 28 percent discount to our fair value while the ethical screen clears without issue.
Forward earnings trade at 15.5 times with revenue rising 4 percent a year. Return on equity reaches 107 percent even though net margins stay thin at 1 percent. A weak moat leaves room for competitors yet the valuation and ethical pass keep the name on the opportunity list.
Thin margins and limited pricing power remain real concerns in a sector that can face sudden regulatory shifts. Low growth also caps how far any rerating might run. Analysis, not advice.
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
COR trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-25Markup$314.69+2.2%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357.
2026-07-25Markup · changed$307.90+11.9%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357.
2026-07-18Distribution$275.04+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are down 0%. Our forward projection puts the odds of a 10% gain over the next month near 18%. The street (12 analysts) rates it buy, with a mean price target of $357.
2026-07-03Distribution$275.04+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Distribution$275.04Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
